en · de · es · fr · pt
peptide-index.peptides7250.com › Blog › Peptide Identity And Receptor Targets — Worked Examples

Peptide Identity And Receptor Targets — Worked Examples

By Editorial Desk · published 2026-05-25 · last reviewed 2026-06-17 · Blog

肽类药物 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2026-06-17. Where a claim depends on a specific study, the study is described rather than over-claimed.

Peptide Identity and Receptor Targets

Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.

Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.

Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.

三重受体激动剂的分子设计

retatrutide 是一种人工合成的多肽,设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子,而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础,经过非天然氨基酸替换和脂肪酸侧链修饰,以获得更长的作用时间。该方向属于多受体激动剂研究的一部分,与双重激动剂的工作并行推进。

三种受体在能量平衡中的分工并不相同:GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节,胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应,也可能出现相互制约,具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标,但协同关系的细节仍处在研究阶段。

Retatrutide at a glance

PropertyValueNotes
Molecular classSynthetic peptide of about 39 residuesBackbone derived from a GIP sequence
Molecular massApproximately 4.7 kDaPeptide chain plus fatty diacid moiety
Receptor targetsGLP-1, GIP, glucagonUnimolecular triple agonist
Typical storage temperature2 to 8 degrees CelsiusProtect from light; avoid repeated freeze-thaw
Common analytical methodLC-MS/MSUsed for plasma quantification and purity checks

Discovery and Triple Receptor Pharmacology

Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.

Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.

Related pages on this site

Analytical Methods and Storage

Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.

Documentation plays a practical role in maintaining consistent results across laboratories. Certificates of analysis list purity, identity, and testing methods, and batch numbers allow comparisons between lots. Records of storage temperature and handling history help investigators interpret unexpected findings. When a sample behaves anomalously, reviewing that documentation often reveals whether the cause lies in the material or in the assay conditions.

Triple Receptor Agonist Background

Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.

Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.

Clinical Endpoints and Analytical Methods

Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.

Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.

Supporting material

The cattle boats were examined, but the dates of the murders did not coincide with a single boat's movements, and the transfer of a crewman between boats was also ruled out. At the end of October, Robert Anderson asked police surgeon Thomas Bond to give his opinion on the extent of the murderer's surgical skill and knowledge. The opinion offered by Bond on the character of the "Whitechapel murderer" is the earliest surviving offender profile. Bond's assessment was based on his own examination of the most extensively mutilated victim and the post mortem notes from the four previous canonical murders. In his opinion the killer must have been a man of solitary habits, subject to "periodical attacks of homicidal and erotic mania", with the character of the mutilations possibly indicating "satyriasis". Bond also stated that "the homicidal impulse may have developed from a revengeful or brooding condition of the mind, or that religious mania may have been the original disease but I do not think either hypothesis is likely".

== External links == Large+Neutral+Amino+Acid-Transporter+1 at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Amino+Acid+Transport+System+L at the U.S. National Library of Medicine Medical Subject Headings (MeSH) This article incorporates text from the United States National Library of Medicine, which is in the public domain.

Adrenocorticotropic hormone (ACTH; also adrenocorticotropin, corticotropin) is a polypeptide tropic hormone produced by and secreted by the anterior pituitary gland. It is also used as a medication and diagnostic agent. ACTH is an important component of the hypothalamic-pituitary-adrenal axis and is often produced in response to biological stress (along with its precursor corticotropin-releasing hormone from the hypothalamus). Its principal effects are increased production and release of cortisol and androgens by the zona fasciculata and zona reticularis, respectively. ACTH is also related to the circadian rhythm in many organisms. Deficiency of ACTH is an indicator of secondary adrenal insufficiency (suppressed production of ACTH due to an impairment of the pituitary gland or hypothalamus, cf. hypopituitarism) or tertiary adrenal insufficiency (disease of the hypothalamus, with a decrease in the release of corticotropin releasing hormone (CRH)). Conversely, chronically elevated ACTH levels occur in primary adrenal insufficiency (e.g. Addison's disease) when adrenal gland production of cortisol is chronically deficient. In Cushing's disease, a pituitary tumor leads to excessive production of ACTH, which stimulates the adrenal cortex to produce high levels of cortisol.

The emergent long elimination timescale appears because not only is the intrinsic degradation time scale an order of magnitude longer than that of binding, but also because the endosomal antibody concentration is low due to high binding affinity. In particular, the analysis shows that clearance in the terminal phase is inherently nonlinear, with clearance,

=== Pharmacodynamics === Methaqualone acts primarily as a sedative, reducing anxiety and inducing sleep. It binds to GABAA receptors, where it functions as a positive allosteric modulator at many receptor subtypes, enhancing the inhibitory effects of the neurotransmitter GABA. It shows negligible affinity for a wide array of other potential targets, including other receptors and neurotransmitter transporters. This action is similar to that of benzodiazepines like diazepam. Unlike most benzodiazepines, however, methaqualone may also act as a negative allosteric modulator at certain GABAA receptor subtypes, producing excitatory effects in neurons expressing those receptors. As such, methaqualone is considered a mixed GABAA receptor modulator. The binding site for methaqualone on the GABAA receptor complex is distinct from those of benzodiazepines, barbiturates, and neurosteroids, though it may partially overlap with the etomidate binding site.

Sources: en.wikipedia.org

Supporting material

== Sources == Rupert, James (14 January 1992). "Christian Knights Claim Key Role in Georgia". The Washington Post. Bonner, Raymond (16 November 1993). "Georgian Fighter Wields Guns, Money and Charm". The New York Times. "Dzhaba Ioseliani, 76; Oft-Imprisoned Leader of Georgian Paramilitary Force". Associated Press. 5 March 2003 – via Los Angeles Times. Corley, Felix (25 March 2003). "Jaba Ioseliani: Violent warlord in post-Communist Georgia". The Independent. "Shevardnadze Is Wounded By Car Bomb In Georgia (Published 1995)". 1995-08-30. Archived from the original on 2024-04-23. Retrieved 2026-01-18. "Georgians Held in Failed Assassination of Shevardnadze". Los Angeles Times. 1995-09-19. Retrieved 2026-01-18. "IOSELIANI AND ACCOMPLICES SENTENCED. - Jamestown". jamestown.org. Retrieved 2026-01-18. "1997 Human Rights Report: Georgia". 1997-2001.state.gov. Retrieved 2026-01-18.

== See also == Allicin, the active piquant flavor chemical in uncooked garlic, and to a lesser extent onions (see those articles for discussion of other chemicals in them relating to pungency, and eye irritation) Capsazepine, capsaicin antagonist Iodoresiniferatoxin, an ultrapotent capsaicin antagonist derived from Resiniferatoxin Naga Viper pepper, Bhut Jolokia Pepper, Carolina Reaper, Trinidad Moruga Scorpion; some of the world's most capsaicin-rich fruits Piperine, the active flavor chemical in black pepper List of capsaicinoids

=== Terrestrial abundance === Perchlorate is created by lightning discharges in the presence of chloride. Perchlorate has been detected in rain and snow samples from Florida and Lubbock, Texas. Naturally occurring perchlorate at its most abundant can be found commingled with deposits of sodium nitrate in the Atacama Desert of northern Chile. These deposits have been heavily mined as sources for nitrate-based fertilizers. Chilean nitrate is in fact estimated to be the source of around 81,000 tonnes (89,000 tons) of perchlorate imported to the U.S. (1909–1997). Results from surveys of ground water, ice, and relatively unperturbed deserts have been used to estimate a 100,000 to 3,000,000 tonnes (110,000 to 3,310,000 tons) "global inventory" of natural perchlorate presently on Earth.

by Kimura). In 1981, Joseph Felsenstein proposed a four-parameter model (F81) in which the substitution rate corresponds to the equilibrium frequency of the target nucleotide. Hasegawa, Kishino, and Yano unified the two last models to a five-parameter model (HKY). After these pioneering efforts, many additional sub-models of the GTR model were introduced into the literature (and common use) in the 1990s. Other models that move beyond the GTR model in specific ways were also developed and refined by several researchers. Almost all DNA substitution models are mechanistic models (as described above). The small number of parameters that one needs to estimate for these models makes it feasible to estimate those parameters from the data. It is also necessary because the patterns of DNA sequence evolution often differ among organisms and among genes within organisms. The later may reflect optimization by the action of selection for specific purposes (e.g. fast expression or messenger RNA stability) or it might reflect neutral variation in the patterns of substitution. Thus, depending on the organism and the type of gene, it is likely necessary to adjust the model to these circumstances.

Sources: en.wikipedia.org

Notes from published material

== History == Phage display was first described by George P. Smith in 1985, when he demonstrated the display of peptides on filamentous phage (long, thin viruses that infect bacteria) by fusing the virus's capsid protein to one peptide out of a collection of peptide sequences. This displayed the different peptides on the outer surfaces of the collection of viral clones, where the screening step of the process isolated the peptides with the highest binding affinity. In 1988, Stephen Parmley and George Smith described biopanning for affinity selection and demonstrated that recursive rounds of selection could enrich for clones present at 1 in a billion or less. In 1990, Jamie Scott and George Smith described creation of large random peptide libraries displayed on filamentous phage. Phage display technology was further developed and improved by groups at the Laboratory of Molecular Biology with Greg Winter and John McCafferty, The Scripps Research Institute with Richard Lerner and Carlos Barbas and the German Cancer Research Center with Frank Breitling and Stefan Dübel for display of proteins such as antibodies for therapeutic protein engineering. Smith and Winter were awarded a half share of the 2018 Nobel Prize in chemistry for their contribution to developing phage display. A patent by George Pieczenik claiming priority from 1985 also describes the generation of peptide libraries.

atomic number (Z) Also proton number. The number of protons found in the nucleus of an atom of a given chemical element. It is identical to the charge number of the nucleus and is used in the periodic table to uniquely identify each chemical element.

== Classification of amines == Amines can be classified according to the nature and number of substituents on nitrogen. Aliphatic amines contain only H and alkyl substituents. Aromatic amines have the nitrogen atom connected to an aromatic ring.

Bergamot essential oil contains a significant amount of bergapten, a phototoxic substance that gets its name from the bergamot orange. Bergapten, a linear furanocoumarin derived from psoralen, is often found in plants associated with phytophotodermatitis. Bergamot essential oil has a higher concentration of bergapten (3000–3600 mg/kg) than any other Citrus-based essential oil. When bergamot essential oil is applied directly to the skin via a patch test, followed by exposure to ultraviolet light, a concentration-dependent phototoxic effect is observed. However, if the oil is twice rectified (and therefore bergapten-free), no phototoxic response is observed. The International Fragrance Association (IFRA) restricts the use of bergamot essential oil due to its phototoxic effects. Specifically, IFRA recommends that leave-on skin products be limited to 0.4% bergamot oil, which is more restrictive than any other Citrus-based essential oil. Although generally recognized as safe for human consumption, bergamot essential oil contains a significant amount of bergamottin, one of two furanocoumarins believed to be responsible for a number of grapefruit–drug interactions. Furanocoumarin contaminants in some berrgamot oil are removed by distillation before the oil is used as a cosmetic.

=== Mesoamerica === By 500 BCE, it was already being cultivated in southern Mexico and probably other areas. A large, lumpy variety of tomato, a mutation from a smoother, smaller fruit, originated in Mesoamerica, and may be the direct ancestor of some modern cultivated tomatoes. The Aztecs raised several varieties of tomato, with red tomatoes called xitomatl. Bernardino de Sahagún reported seeing a great variety of tomatoes in the Aztec market at Tenochtitlán (Mexico City): "large tomatoes, small tomatoes, leaf tomatoes, sweet tomatoes, large serpent tomatoes, nipple-shaped tomatoes", and tomatoes of all colors from the brightest red to the deepest yellow. Sahagún mentioned Aztecs cooking various sauces, some with tomatoes of different sizes, serving them in city markets: "foods sauces, hot sauces; ... with tomatoes, ... sauce of large tomatoes, sauce of ordinary tomatoes, ..."

Sources: en.wikipedia.org

Frequently asked questions

Is retatrutide available as a medicine?

As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.

How does it compare with dual GLP-1 and GIP agonists?

Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.

How is the compound named in reporting?

Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.

三重激动指的是什么?

指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。

Network